Atea Pharmaceuticals Inc (AVIR)
3.00
-0.05
(-1.64%)
USD |
NASDAQ |
Mar 24, 16:00
2.995
0.00 (0.00%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 250.02M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -58.79% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 0.7108 |
| Price to Book Value | 0.3903 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
News
Headline
Wire
Time (ET)
MT Newswires
03/16 09:26
Globe Newswire
03/14 07:00
Globe Newswire
03/08 07:00
Yahoo
02/28 16:05
Yahoo
02/23 07:00
Globe Newswire
02/21 07:00
Yahoo
02/15 16:05
Yahoo
02/13 08:22
Globe Newswire
02/07 07:00
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 05/10/2023* | 08:00 EST | Earnings Call | Q1 2023 | -- | -- | -- | |
| 05/10/2023* | -- | Results | Q1 2023 | -- | -0.48 | -- | |
| 02/28/2023 | 16:30 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 02/28/2023 | -- | Results | Q4 2022 | -0.41 | -0.45 | 9.03% | |
| 11/07/2022 | 16:30 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 11/07/2022 | -- | Results | Q3 2022 | -0.10 | -0.44 | 77.43% | |
| 08/08/2022 | 16:30 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 08/08/2022 | -- | Results | Q2 2022 | -0.38 | -0.49 | 22.71% |
*Estimated Date/Time
Earnings
Profile
Edit
| Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in discovering and developing therapies to address the unmet medical needs of patients with severe viral diseases. Its programs are focused on the development of orally- administered direct acting antivirals for the treatment of patients with COVID-19 in the hospital and community settings, the treatment of patients with chronic hepatitis C infection, the treatment of patients with dengue, and the treatment of high-risk patients with severe respiratory syncytial virus infection. The company's medicinal chemistry, virology, and pharmacology expertise, bolstered by its collective experience in drug development, enables it to pioneer new advancements in antiviral science. |
| URL | https://www.ateapharma.com |
| Investor Relations URL | https://ir.ateapharma.com/ |
| HQ State/Province | Massachusetts |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | N/A |
| Next Earnings Release | May. 10, 2023 (est.) |
| Last Earnings Release | Feb. 28, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | -- |
| Cash Payout Ratio | -- |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 24, 2023.
Fundamentals
| Revenue (TTM) | -- |
| Total Expenses (TTM) | 130.65M |
| Net Income (TTM) | -115.91M |
| Total Assets (Quarterly) | 666.71M |
| Total Liabilities (Quarterly) | 26.14M |
| Shareholders Equity (Quarterly) | 640.57M |
| Cash from Operations (TTM) | -120.98M |
| Cash from Investing (TTM) | -455.41M |
| Cash from Financing (TTM) | 0.37M |
Ratings
Profile
Edit
| Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in discovering and developing therapies to address the unmet medical needs of patients with severe viral diseases. Its programs are focused on the development of orally- administered direct acting antivirals for the treatment of patients with COVID-19 in the hospital and community settings, the treatment of patients with chronic hepatitis C infection, the treatment of patients with dengue, and the treatment of high-risk patients with severe respiratory syncytial virus infection. The company's medicinal chemistry, virology, and pharmacology expertise, bolstered by its collective experience in drug development, enables it to pioneer new advancements in antiviral science. |
| URL | https://www.ateapharma.com |
| Investor Relations URL | https://ir.ateapharma.com/ |
| HQ State/Province | Massachusetts |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | N/A |
| Next Earnings Release | May. 10, 2023 (est.) |
| Last Earnings Release | Feb. 28, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| QCSGX | 5.815M USD | 1.03% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| AVIR Tweets |